RT Journal Article
SR Electronic
T1 Biomarkers in Psoriasis and Psoriatic Arthritis: GRAPPA 2008
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 462
OP 467
DO 10.3899/jrheum.090957
VO 37
IS 2
A1 CHRISTOPHER T. RITCHLIN
A1 ABRAR A. QURESHI
A1 KURT de VLAM
A1 COSTANTINO PITZALIS
A1 PHILIP S. HELLIWELL
A1 PHILIP J. MEASE
A1 DAFNA D. GLADMAN
A1 GERALD G. KRUEGER
A1 ARTHUR F. KAVANAUGH
A1 OLIVER FITZGERALD
YR 2010
UL http://www.jrheum.org/content/37/2/462.abstract
AB Biomarkers can provide valuable insights into disease susceptibility and natural history and may serve as surrogate endpoints for a variety of different outcomes. At the 2008 annual meeting of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis), members were updated on the development of biomarkers in psoriatic arthritis (PsA). Plenary presentations included a translational approach to biomarker development (Christopher Ritchlin, University of Rochester, NY, USA), biomarkers for psoriasis (Abrar Qureshi, Harvard Medical School, MA, USA), new data on biomarkers for damage in PsA (Kurt de Vlam, University Hospitals Leuven, Belgium), and design considerations for a longitudinal study of joint damage being undertaken under the OMERACT umbrella with colleagues working on rheumatoid arthritis and ankylosing spondylitis (Costantino Pitzalis, Barts and the London School of Medicine, London, UK; Oliver FitzGerald, St. Vincent’s Hospital, Dublin, Ireland). At the conclusion of this session, the meeting attendees discussed specific design issues of the proposed longitudinal study, including study duration, disease process core domains, and the instruments to be used in recording enthesitis, dactylitis, nail involvement, quality of life and structural damage. The appearance of new therapeutic options in PsA raises the need for sensitive biomarkers for both disease activity and outcome.